LL-37 (Human Cathelicidin Antimicrobial Peptide)
PeptideThe slightly negative divergence value reflects that community users assess LL-37 with similar caution to the medical community — albeit for different reasons: medical evidence is limited to topical wound healing [s6, s7], while the community primarily raises concerns about product quality and injection safety [c1, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
LL-37 has genuinely compelling biology — pathogen membrane lysis, immune modulation, wound healing — but the gap between preclinical data and human safety evidence is substantial. The FDA has explicitly flagged LL-37 as a peptide with insufficient human safety data, and the risk of triggering or worsening autoimmune conditions like psoriasis and SLE is mechanistically grounded, not speculative. Community reports are sparse, methodologically worthless, and dominated by uncertainty about dosing and product quality — grey-market products without sterility controls add further risk. Anyone with psoriasis, SLE, or another Th17-mediated autoimmune condition should strictly avoid LL-37.
Description
Endogenous antimicrobial peptide (37 amino acids) from the cathelicidin family; modulates immune defense, promotes wound healing, and exhibits antiviral activity [s1, s2].
LL-37 is the only known human cathelicidin, encoded by the CAMP gene. It is produced as the precursor molecule hCAP-18 by neutrophils, epithelial cells, and other immune cells, and is processed extracellularly by serine proteases into the active 37-amino-acid peptide LL-37 [s1, s3]. The name derives from the two N-terminal leucine residues and the total length of 37 amino acids [s2]. The peptide is present at multiple body barriers — skin, airway mucosa, intestinal epithelium, and urogenital tract — where it acts as a first line of defense against pathogens [s3]. Beyond its direct antimicrobial activity against bacteria, viruses, and fungi, LL-37 possesses pronounced immunomodulatory properties: it activates Toll-like receptors, promotes chemotaxis of immune cells, neutralizes bacterial endotoxins (LPS), and transactivates the EGF receptor on epithelial cells [s4, s5]. Clinically, LL-37 has been investigated in Phase I/II studies for the treatment of hard-to-heal venous ulcers (venous leg ulcers) and in a Phase 2 study in diabetic foot ulcers [s6, s7]. Results demonstrated improved healing rates without serious systemic safety concerns [s7]. Outside controlled clinical trials, human use is not sufficiently substantiated. In the biohacking community, LL-37 is increasingly discussed as an injectable peptide for immune enhancement and wound healing, although no controlled human data exist for systemic self-administration [s13, s14]. The FDA has classified LL-37 as a substance with limited human safety data for systemic use [s13].
Legal Status (DE)
LL-37 is not approved as a medicinal product in Germany, Austria, or Switzerland, and is not marketable as a dietary supplement. It is distributed exclusively as a research chemical labeled "Research Use Only / Not for Human Use." Human use outside of clinical trials is not legally covered and violates the Medicinal Products Act (AMG) [s15, s16].
Mechanism of Action
LL-37 acts via multiple complementary mechanisms [s1, s3, s4, s5]: 1. Direct antimicrobial activity: The cationic, amphipathic peptide interacts electrostatically with the negatively charged membranes of bacteria, fungi, and enveloped viruses. Insertion into the membrane and pore formation disrupts membrane integrity, leading to pathogen cell death [s1, s3]. At higher concentrations, LL-37 can also interact with eukaryotic cell membranes, which accounts for its cytotoxicity [s8]. 2. Immunomodulation: LL-37 binds and neutralizes bacterial lipopolysaccharides (LPS), thereby preventing excessive inflammatory responses (sepsis prevention) [s5]. It promotes chemotaxis of neutrophils, monocytes, and T cells to sites of infection and accelerates pathogen clearance [s5]. 3. EGF receptor transactivation: LL-37 transactivates the epidermal growth factor receptor (EGFR) on epithelial cells, promoting cell migration, proliferation, and re-epithelialization of wounds [s4]. 4. Antiviral activity: LL-37 disrupts replication of enveloped RNA viruses (e.g., RSV, influenza) through direct interaction with viral envelopes and modulation of intracellular Ca2+ signaling pathways, thereby enhancing IFN-β production [s9, s10]. 5. Autoimmune relevance: In pathological contexts (psoriasis, SLE), LL-37 can bind self-DNA/RNA and stimulate pDCs to produce type I IFN, potentially triggering autoreactive processes [s11]. Biosynthesis of LL-37 is upregulated by vitamin D3 via the vitamin D receptor (VDR) at the CAMP gene promoter [s3].
Dosing
Wundheilung (topisch, klinische Studie)
- Dose
- Topical application; exact concentration not publicly standardized in clinical studies
- Frequency
- gemäß Studienprotokoll
- Route
- topisch
- Duration
- bis zu 12 Wochen
- Timing
- Wound dressing, direct application
- With food
- optional
Systemisch/subkutan (anekdotisch, Biohacking-Community, NICHT klinisch validiert)
- Dose
- 50–400 mcg daily, stepwise titration starting at 50 mcg
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- 8–16 Wochen (anekdotisch)
- Timing
- No validated recommendation
- With food
- optional
No validated upper limits for systemic human use. In animal studies, a dose of 100 µg/kg showed no observable toxicity, while 3,000 µg/kg caused toxic organ effects [s8]. No established safety thresholds exist for humans.
All dosing information for subcutaneous self-administration is based exclusively on user reports without clinical validation. LL-37 is not an approved medicinal product. Human use outside of clinical trials is not recommended by regulatory authorities [s13, s15].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injektionsstellen-Reaktionen (Rötung, Schwellung, Schmerz) Due to the pro-inflammatory properties of LL-37, injection site reactions are more pronounced than with other peptides [s12]. Clinical observations with topical application showed local tolerability issues [s7]. | häufig | leicht |
| Hämolyse und Toxizität gegenüber Leukozyten und T-Lymphozyten In vitro data show that LL-37 can induce hemolysis and damage immune cells via hydrophobic interactions with eukaryotic membranes [s8]. Clinical relevance at therapeutic doses in humans is unclear. | theoretisch | moderat |
| Auslösung oder Verschlechterung von Autoimmunreaktionen (Psoriasis, SLE) LL-37 can bind self-DNA/RNA and stimulate pDCs to produce type I IFN, which may trigger or exacerbate autoreactive processes in genetically predisposed individuals [s11]. | theoretisch | schwer |
| Systemische Organtoxizität bei hohen Dosen In an animal model (rat), high doses (3,000 µg/kg) caused organ toxicity. Transferability to humans is unknown [s8]. | theoretisch | schwer |
| Kontaminationsrisiken bei nicht-sterilen Research-Chemical-Produkten Purchasing LL-37 as a research chemical carries risks from contaminants, immune reactions, and inadequate product characterization [c3, s15]. | gelegentlich | schwer |
Contraindications
LL-37 plays a pathogenic role in psoriasis by activating pDCs and stimulating type I IFN production and autoreactive Th17 cells. Exogenous administration could worsen the disease [s11].
LL-37 has been identified as an autoantigen in SLE pathogenesis. Citrullinated LL-37 stimulates autoreactive T cells and autoantibody production [s11].
Uncontrolled immunomodulation by exogenous LL-37 in immunocompromised patients is unstudied; risk of atypical immune reactions exists theoretically [s1, s5].
No safety data available for exogenous systemic LL-37 administration during pregnancy or lactation.
Interactions
Synergistic
Vitamin D3 upregulates endogenous LL-37 production via the VDR at the CAMP gene promoter. The combination could synergistically enhance endogenous cathelicidin production [s3].
Anecdotal community reports of combination with Tα1 for immunomodulation; no clinical data [c1].
LL-37 and BPC-157 are frequently combined to repair the intestinal mucosa and strengthen mucosal immune defense. Both peptides promote wound healing and tissue regeneration via complementary mechanisms.
Zinc stimulates LL-37 secretion from intestinal epithelial cells via ERK and p38 MAP kinase signaling pathways. Zinc supplementation may increase endogenous cathelicidin production.
Long-chain fatty acids, including omega-3 fatty acids, can enhance LL-37 synthesis and reduce inflammatory risks when combined with antimicrobial peptides. Co-administration may improve healing outcomes.
LL-37 and KPV both exert anti-inflammatory effects via NF-κB signaling pathways and are recommended in the community for combination use in immunomodulation and GI inflammation reduction.
Caution
Potentially antagonistic interaction, as LL-37 activates pro-inflammatory signaling pathways that are inhibited by immunosuppressants. Interactions have not been clinically investigated.
LL-37 has been associated with thrombotic complications in COVID-19. Interactions with anticoagulants are theoretically possible but not clinically established [s10].
Studies
Tier A — High Evidence
Effect Size: Phase IIb RCT (n = 148); two LL-37 arms (0.5 and 1.6 mg/mL) versus placebo; efficacy analysis of the total study population showed no significant improvement in wound healing compared to placebo (primary endpoint not reached).
Effect Size: Healing rate constants for 0.5 mg/mL LL-37 approximately sixfold higher than placebo (p = 0.003); for 1.6 mg/mL approximately threefold higher (p = 0.088); n = 34 patients, 4-week double-blind treatment phase, twice-weekly topical application.
Tier B — Moderate Evidence
Outcome: Granulation index (wound healing) at days 7, 14, 21, and 28
Effect Size: Granulation index in the LL-37 group was significantly higher than in the placebo group at all time points (p = 0.031 / 0.009 / 0.006 / 0.037 at day 7/14/21/28). No significant difference in IL-1α, TNF-α, or aerobic bacterial colonization.
Community Evidence
Top reported benefits
- Anecdotal reports of improved wound healing following subcutaneous application
- Subjectively perceived immune enhancement in infection-prone individuals
- Combination with BPC-157 or Thymosin Alpha-1 is being discussed
Top reported issues
- Pronounced injection site reactions (redness, burning, swelling)
- Uncertainty about correct dosing and reconstitution
- Doubts about product quality and purity from research chemical suppliers
- High cost compared to other peptides
The FDA has explicitly classified LL-37 as a peptide with limited human safety data and flagged it as a potential safety risk in the context of non-sterile research chemical products [c3]. Pharmazeutische Zeitung (Germany) reported on LL-37 as one of the FDA-flagged risk peptides, citing concerns regarding contamination and immune reactions [c3]. Individuals with autoimmune conditions (psoriasis, SLE) should strictly avoid LL-37 [s11]. Very few evaluable individual experience reports from the DACH community are available; overall data for community scoring is very sparse.
Scientific Sources
- Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Mahlapuu M, Sidorowicz A, Gerstberger BS, et al. (2021). Wound Repair and RegenerationAPMID:34694038DOI - LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity
Mookherjee N, Anderson MA, Haagsman HP, et al. (2024). International Journal of Antimicrobial Agents (ScienceDirect)BDOI - Role of LL-37 in thrombotic complications in patients with COVID-19
Soehnlein O, Lindbom L, Weber C, et al. (2022). PMC / Frontiers in ImmunologyBLink - Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease
Kahlenberg JM, Kaplan MJ (2013). Journal of Immunology / PMCBLink - LL-37: The Antimicrobial Peptide for Innate Immunity — Julian Douwes M.D.
Douwes J (2024). juliandouwes.com (medizinischer Blog)DLink - FDA Peptide Reclassification 2026: Which Peptides Are Coming Back
Peptide Database Editorial Team (2026). peptide-db.comDLink - LL-37: Antimicrobial Peptide Research Overview
PeptideJournal Editorial (2024). PeptideJournal.orgDLink - LL-37 in Deutschland kaufen | Peptid LL-37 zu verkaufen
HCS Pharma (2024). hcs-pharma.comDLink - Peptide in Deutschland & EU: Rechtslage, Zulassung & Strafbarkeit
Elmntlab Editorial (2024). elmntlab.deDLink - Antimicrobial Properties and Cytotoxicity of LL-37-Derived Synthetic Peptides to Treat Orthopedic Infections
Wnorowska U, Fiedoruk K, Piktel E, et al. (2024). PMC / AntibioticsCLink - Peptid-Hype in Tech-Kreisen
Pharmazeutische Zeitung Redaktion (2025). Pharmazeutische ZeitungBLink - Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial
Miranda E, Bramono K, Yunir E, Reksodiputro MH, Suwarsa O, Rengganis I, Harahap AR, Subekti D, Suwarto S, Hayun H, Bardosono S, Baskoro JC (2023). Archives of Dermatological ResearchCDOI - LL-37 – Wikipedia (Deutsch)
Wikipedia-Autoren (2024). Wikipedia DEDLink - Die Wirkung von Vitamin D3-Analoga auf die Cathelicidin-Expression (Dissertation)
Gross K (2012). Ludwig-Maximilians-Universität München (edoc)CLink - The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor
Tjabringa GS, Aarbiou J, Ninaber DK, et al. (2003). Journal of ImmunologyCPMID:14662872 - Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update
Kanthawong S, Nazmi K, Wongratanachewin S, et al. (2025). Inflammation Research (Springer Nature)BDOI - Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Grönberg A, Mahlapuu M, Ståhle M, et al. (2022). Wound Repair and Regeneration / PMCALink - Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Grönberg A, Mahlapuu M, Ståhle M, et al. (2014). Wound Repair and RegenerationADOI - Cationic Antimicrobial Peptide LL-37 Is Effective against both Extra- and Intracellular Staphylococcus aureus
Sandgren S, Wittrup A, Cheng F, et al. (2012). Antimicrobial Agents and ChemotherapyCDOI - Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca2+-dependent mechanism
Bergman P, Raqib R, Rekha RS, et al. (2025). PMC / Respiratory ResearchCLink
Community Sources
Storage
Unopened
Lyophilized powder: store at -20 °C, protected from light and moisture.
Opened
Reconstituted solution (bacteriostatic water): store at 4 °C, protected from light; use within 28 days recommended.
Notes
Peptides are susceptible to degradation from repeated freeze-thaw cycles. Aliquoting prior to storage is recommended. Sterility of research chemical products is not guaranteed [s15].